Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PTPRA | P18433 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4267927 | 1.00 | MAPT (0.35) | MAPTHTTKMT2ADNMT1KDM4E | |
| SCHEMBL3194680 | 0.78 | PTPRA (0.46) | MAPTKMT2AKDM4EPTPRACYP2C19 | |
| SCHEMBL3194682 | 0.78 | PTPRA (0.46) | MAPTKMT2AKDM4EPTPRACYP2C19 | |
| SCHEMBL11109785 | 0.73 | MAPT (0.31) | MAPTKMT2AKDM4EALDH1A1POLB | |
| SCHEMBL4267930 | 0.72 | MAPT (0.33) | MAPTHTTKMT2AKDM4EALDH1A1 | |
| SCHEMBL16318734 | 0.71 | TXNRD1 (0.43) | MAPTHTTKMT2AKDM4EALDH1A1 | |
| SCHEMBL3811168 | 0.71 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL11389549 | 0.71 | TSHR (0.39) | ALDH1A1 | |
| SCHEMBL6131656 | 0.71 | SIRT2 (0.31) | ALDH1A1 | |
| SCHEMBL14324382 | 0.70 | CYP3A4 (0.33) | MAPTKMT2AKDM4EPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608612-B2 | Radiosensitizer formulations and methods for use | Matthews, Richard H. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20060193917-A1 | Radiosensitizer formulations and methods for use | MATTHEWS, RICHARD H., DR. | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060193917-A1 | Radiosensitizer formulations and methods for use | NOS2, IDH1, HNMT | MAPT 3354/4885HTT 1790/4885KMT2A 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.